Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069393 | 0.95 | PIK3CD (0.55) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL4327116 | 0.93 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL5502986 | 0.93 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL3430972 | 0.89 | PIK3CD (0.66) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL628723 | 0.86 | PIK3CD (0.50) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL9812335 | 0.86 | PIK3CD (0.50) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL22021621 | 0.86 | PIK3CD (0.53) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL1978043 | 0.84 | PIK3CD (0.51) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL7005443 | 0.84 | PIK3CD (0.61) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL12197894 | 0.83 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444028-B | Extractant for separating 2, 4-dichlorotoluene and 2, 5-dichlorotoluene and separation method | 江苏聚由新材料科技有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-113444028-A | Extractant for separating 2, 4-dichlorotoluene and 2, 5-dichlorotoluene and separation method | 江苏超跃化学有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113444028-B | Extractant for separating 2, 4-dichlorotoluene and 2, 5-dichlorotoluene and separation method | 江苏聚由新材料科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADOVATE, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADOVATE, LLC | 2022-12-22 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| CN-100395233-C | N,N-dialkyl-2-pyrrolidone quaternary ammonium salt and its synthesizing method and use | UNIV WUHAN (CN) | 2008-06-18 | — | — | CN | disclosed |
| US-7323490-B2 | Pyrrole compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | SHEWCHUK LISA M | 2007-01-11 | — | — | US | disclosed |
| CN-1775753-A | N,N-dialkyl-2-pyrrolidone quaternary ammonium salt and its synthesizing method and use | UNIV WUHAN (CN) | 2006-05-24 | — | — | CN | disclosed |
| WO-2005068437-A1 | 2, 4 - DIAMINOPYRIMIDINES AND THEIR USE FOR INDUCING CARDIOMYOGENESIS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADORA2B, ADORA2A, ADORA3 | PIK3CD 3213/4885LMNA 2180/4885KMT2A 2059/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PIK3CD 1445/4885LMNA 2238/4885KMT2A 4102/4885 |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | FAM20C, FRS2, FRK | PIK3CD 243/4885LMNA 3276/4885KMT2A 3069/4885 |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, HCRTR2 | PIK3CD 2533/4885LMNA 4693/4885KMT2A 2919/4885 |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CD 3085/4885LMNA 2057/4885KMT2A 2629/4885 |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | IL2, MALT1, FCGRT | PIK3CD 1655/4885LMNA 4875/4885KMT2A 947/4885 |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | PIK3CD 1025/4885LMNA 3192/4885KMT2A 3796/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | PIK3CD 2643/4885LMNA 3638/4885KMT2A 481/4885 |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | PPIG, AQP3, AQP1 | PIK3CD 1426/4885LMNA 195/4885KMT2A 4864/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | PIK3CD 3381/4885LMNA 4039/4885KMT2A 926/4885 |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | CUTA, IAPP, CRYAA | PIK3CD 3669/4885LMNA 670/4885KMT2A 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.